Subcutaneously injectable insulin formulations and methods of administration

An ultra fast-acting subcutaneously injectable insulin formulation comprising a solvated complex of a diketopiperazine and a monomeric insulin in an aqueous solution at a pH of about 6.0 to about 7.2. An ultra fast-acting subcutaneously injectable insulin formulation comprising a monomeric in an aqu...

Full description

Saved in:
Bibliographic Details
Main Authors RHODES, Christopher A, D'SOUZA, Lawrence, STEINER, Solomon S
Format Patent
LanguageEnglish
Published 31.03.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:An ultra fast-acting subcutaneously injectable insulin formulation comprising a solvated complex of a diketopiperazine and a monomeric insulin in an aqueous solution at a pH of about 6.0 to about 7.2. An ultra fast-acting subcutaneously injectable insulin formulation comprising a monomeric in an aqueous solution with one or more excipients, excluding a diketopiperazine, at a pH of about 6.0 to about 7.2. An ultra fast-acting subcutaneously injectable insulin formulation comprising a solvated complex of a diketopiperazine and a monomeric insulin, wherein the diketopiperazine is 2,5-diketo-3,6- di(4-fumarylaminobutyl) piperazine. A stabilized subcutaneously injectable glucagon formulation comprising a solvated complex of a diketopiperazine and glucagon in an aqueous solution at a pH of about 6.4 to about 7.9. A stabilized subcutaneously injectable glucagon formulation comprising glucagon in an aqueous solution with one or more excipients, excluding a diketopiperazine, at a pH of about 6.4 to about 7.9.
Bibliography:Application Number: AU20200351154